2020 will be remembered as the year of the biotech sector. Amid the ongoing pandemic, biotech stocks have taken center stage, with the names developing COVID-19 solutions being catapulted to remarkable highs. But, after posting such jaw-dropping gains, where do these stocks go from here? Morgan Stanley’s Chief U.S. Equity Strategist Mike Wilson says the story could get even better. Doubling down on his optimistic stance, he argues stimulus packages that support consumer demand as well as cost-cutting measures could be catalysts that spur strong showings in 2021. “We think that a return of topline growth and a material reduction …read more
Source:: Yahoo Finance
